Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262593 | 0.90 | HPGD (0.45) | USP2SMN1; SMN2EPHX2CYP11B2USP30 | |
| SCHEMBL6228410 | 0.89 | USP2 (0.55) | USP2SMN1; SMN2EPHX2HPGDTSHR | |
| SCHEMBL9948317 | 0.88 | HPGD (0.48) | USP2SMN1; SMN2EPHX2CYP11B2USP30 | |
| SCHEMBL12384327 | 0.85 | USP2 (0.48) | USP2SMN1; SMN2EPHX2HPGDRECQL | |
| SCHEMBL16590451 | 0.84 | USP2 (0.46) | USP2SMN1; SMN2EPHX2CYP11B2USP30 | |
| SCHEMBL30254327 | 0.84 | USP2 (0.46) | USP2SMN1; SMN2EPHX2CYP11B2USP30 | |
| SCHEMBL12445300 | 0.84 | USP2 (0.46) | USP2SMN1; SMN2EPHX2CYP11B2USP30 | |
| SCHEMBL25341405 | 0.83 | USP2 (0.45) | USP2SMN1; SMN2EPHX2CYP11B2USP30 | |
| SCHEMBL938773 | 0.83 | HPGD (0.49) | USP2SMN1; SMN2EPHX2HPGDTSHR | |
| SCHEMBL21811041 | 0.83 | USP2 (0.45) | USP2SMN1; SMN2EPHX2CYP11B2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-114716381-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114605327-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114573510-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114591223-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-114591242-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119110802-A | Heterocyclic derivatives substituted with a middle or macrocyclic benzyl group and related uses | 森特萨制药(英国)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-114634447-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | FERRING B. V. | 2005-02-24 | — | — | US | disclosed |
| US-20040235752-A1 | 3-fluoro-pyrrolidines as antidiabetic agents | FERRING B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1446116-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2004-08-18 | — | — | EP | disclosed |
| EP-1399154-A1 | 3-FLUORO-PYRROLIDINES AS ANTIDIABETIC AGENTS | Ferring BV (NL) | 2004-03-24 | — | — | EP | disclosed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003035057-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2003-05-01 | — | — | WO | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| WO-2003000250-A1 | 3-FLUORO-PYRROLIDINES AS ANTIDIABETIC AGENTS | FERRING BV (NL) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235752-A1 | 3-fluoro-pyrrolidines as antidiabetic agents | DPP4, DPP7, DPP3 | USP2 2530/4885SMN1; SMN2 4450/4885EPHX2 2439/4885 |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | USP2 2612/4885SMN1; SMN2 2767/4885EPHX2 4184/4885 |
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP9, DPP3 | USP2 309/4885SMN1; SMN2 3159/4885EPHX2 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.